International Journal of Drug Delivery Technology
Volume 16, Issue 2, 2026

Development and Evaluation of Nanocarrier-Loaded Nasal Gel for Enhanced Drug Delivery

Ms. Aaditi S. Punekar1*, Dr. Abhijeet D. Kulkarni1

1School of Pharmaceutical Sciences, Sandip University, Nashik

*Corresponding Author: Ms. Aaditi S. Punekar, Email: aaditipunekar789@gmail.com


ABSTRACT

Objective: To develop and evaluate a nano-carrier–based nasal gel of Benincasa hispida fruit extract (EEBH) for enhanced nasal retention, controlled release, and improved neuroprotective efficacy.

Methods: Liposome- and nanocochleate-loaded nasal gels were prepared using Poloxamer 188 and Carbopol 934P and optimized via statistical design. Formulations (GF1–GF13) were assessed for physicochemical properties including pH, viscosity, gel strength, spreadability, and drug content. In vitro and ex vivo diffusion studies were conducted to evaluate drug release. Neuroprotective activity was studied in scopolamine-induced memory-impaired rats using behavioral models such as Morris Water Maze and Y-maze models.

Results: All formulations showed good clarity and stability. The optimized formulation (GF6) exhibited suitable pH (6.5), high viscosity (1124.2 cP), good gel strength (59 s), high spreadability (24.5 cm²/min), and drug content (94.19%). GF6 demonstrated sustained drug release (>95%) following zero-order kinetics. Behavioral studies showed significant improvement in learning and memory.

Conclusion: The developed nano-carrier nasal gel of Benincasa hispida showed improved drug delivery and significant neuroprotective effects, suggesting its potential as a promising natural therapy for neurodegenerative disorders.

Keywords: Nano-carrier; Nanocochleates; Thermosensitive nasal gel; Benincasa hispida; Poloxamer 188; Controlled drug release; Alzheimer's Disease

How to cite this article: Punekar AS, Kulkarni AD. Development and Evaluation of Nanocarrier-Loaded Nasal Gel for Enhanced Drug Delivery. Int J Drug Deliv Technol. 2026;16(2): 620-629. DOI: 10.25258/ijddt.16.2.66

Source of support: Nil.

Conflict of interest: None